References
- Andersen P. H., Groenvald F. C., Hohlweg R., Hansen L. B., Guddal E., Braestrup C., Nielsen E. B. NNC 01–0112, NNC 01–687 and NNC 01–0756, new selective and highly potent dopamine D1 receptor antagonists. European Journal of Pharmacology 1991, Submitted
- Gombar C. T., Straub K., Levandoski P., Gutzait L., Swayzdis J., Garvie C., Joseph G., Poth B. D., Mico B. A. Pharmacokinetics, metabolism, and disposition of 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine (SK&F 86466) in rats and dogs. Drug Metabolism and Disposition 1986; 14: 540–548
- Hansen K. T., Faarup P., Bundgaard H. Carbamate ester prodrugs of dopaminergic compounds: Synthesis stability and bioconversion. Journal of Pharmaceutical Sciences 1991a; 80: 1–6
- Hansen K. T., Jansen J. A., Mengel H., Christensen J. V., Bundgaard H. Enhanced bioavailability of a new class of dopamine D-1 antagonists following oral administration of their carbamic acid ester prodrugs to dogs. International Journal of Pharmaceutics 1991b, In press
- Holt B., Lowe P. A. Reaction of ortho-hydroxyaldehydes with dimethylsulphoxonium methylide. Tetrahedron Letters 1966; 683–686
- Straub K., Davis M., Hwang B. Benzozepine metabolism revisited. Evidence for the formation of novel amine conjugates. Drug Metabolism and Disposition 1988; 16: 359–366
- Waddington J. L. Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology. General Pharmacology 1988; 19: 55–60
- Waddington J. L., O'Boyle K. M. Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist. Pharmacology and Therapeutics 1989; 43: 1–52
- Weinstock J., Hieble J. P., Wilson J. W., III. The chemistry and pharmacology of 3-benzazepine derivatives. Drugs of the Future 1985; 10: 645–697